MX386476B - Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo. - Google Patents

Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.

Info

Publication number
MX386476B
MX386476B MX2018006226A MX2018006226A MX386476B MX 386476 B MX386476 B MX 386476B MX 2018006226 A MX2018006226 A MX 2018006226A MX 2018006226 A MX2018006226 A MX 2018006226A MX 386476 B MX386476 B MX 386476B
Authority
MX
Mexico
Prior art keywords
hydroxytryptamine
enhance
stimulating agent
receptor stimulating
vivo graft
Prior art date
Application number
MX2018006226A
Other languages
English (en)
Other versions
MX2018006226A (es
Inventor
Fabrice Bruno Chretien
Pierre Rocheteau
Raphael Gaillard
Original Assignee
Pasteur Institut
Centre Hospitalier Sainte Anne Paris
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Hospitalier Sainte Anne Paris, Univ Paris Descartes filed Critical Pasteur Institut
Publication of MX2018006226A publication Critical patent/MX2018006226A/es
Publication of MX386476B publication Critical patent/MX386476B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/30—Materials or treatment for tissue regeneration for muscle reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la medicina regenerativa, y más particularmente a la mejora del potencial de injerto in vivo de material biológico que será administrado a un sujeto en necesidad del mismo.
MX2018006226A 2015-11-20 2016-07-15 Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo. MX386476B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257816P 2015-11-20 2015-11-20
EP16305446 2016-04-15
PCT/EP2016/066965 WO2017084774A1 (en) 2015-11-20 2016-07-15 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential

Publications (2)

Publication Number Publication Date
MX2018006226A MX2018006226A (es) 2018-11-09
MX386476B true MX386476B (es) 2025-03-18

Family

ID=55806270

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006226A MX386476B (es) 2015-11-20 2016-07-15 Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.

Country Status (10)

Country Link
US (2) US11013830B2 (es)
EP (1) EP3377051B1 (es)
JP (1) JP6847946B2 (es)
KR (1) KR20180102071A (es)
CN (1) CN108697670A (es)
AU (1) AU2016356504B2 (es)
BR (1) BR112018010066A8 (es)
CA (1) CA3005396A1 (es)
MX (1) MX386476B (es)
WO (1) WO2017084774A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3324952B1 (en) 2015-07-17 2020-12-16 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
EP3659672A1 (en) * 2018-11-28 2020-06-03 Institut Gustave Roussy Combined use of selective serotonin reuptake inhibitors and hematopoietic growth factors for treating hematopoietic diseases
CN109851573B (zh) * 2018-12-07 2022-11-18 华南理工大学 一种沃替西汀氨基酸酰胺类化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2007044005A1 (en) 2005-10-06 2007-04-19 Tubular Fabricators Industry, Inc. Replaceable hand grip
KR20090028712A (ko) * 2006-06-16 2009-03-19 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ｈｔ3 및 5-ｈｔ1ａ 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
JP2009545522A (ja) * 2006-06-22 2009-12-24 ラモット アット テル アビブ ユニバーシティ， リミテッド 末梢系限定的活性を有する薬としての新規なセロトニン再取り込み阻害剤
US20100092454A1 (en) 2006-12-22 2010-04-15 Enrico De Vivo novel use of antidepressant compounds and related compositions
GB0907350D0 (en) 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
CA2813648C (en) * 2010-10-15 2019-06-25 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
WO2012174537A2 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Small molecule screening for mouse satellite cell proliferation
GB201120259D0 (en) * 2011-11-24 2012-01-04 Univ Gent Allogeneic immune response control
EP2934530A1 (en) * 2012-12-21 2015-10-28 MAP Pharmaceuticals, Inc. Fluoroergoline derivatives and uses thereof
US20160101093A1 (en) 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
EP3324952B1 (en) 2015-07-17 2020-12-16 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
EP3362058B1 (en) 2015-10-14 2021-09-01 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2018011382A1 (en) 2016-07-15 2018-01-18 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair

Also Published As

Publication number Publication date
JP2018534325A (ja) 2018-11-22
AU2016356504B2 (en) 2022-01-20
US11013830B2 (en) 2021-05-25
US20210330863A1 (en) 2021-10-28
BR112018010066A8 (pt) 2022-11-22
WO2017084774A1 (en) 2017-05-26
AU2016356504A8 (en) 2018-06-28
EP3377051B1 (en) 2022-03-30
JP6847946B2 (ja) 2021-03-24
US20180326121A1 (en) 2018-11-15
MX2018006226A (es) 2018-11-09
BR112018010066A2 (pt) 2018-11-13
CN108697670A (zh) 2018-10-23
EP3377051A1 (en) 2018-09-26
AU2016356504A1 (en) 2018-06-21
CA3005396A1 (en) 2017-05-26
KR20180102071A (ko) 2018-09-14

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
GEAP202115055A (en) Anti-cd27 antibodies
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
MX378273B (es) Compuestos activos hacia bromodominios.
MX2016010835A (es) Terapeuticos dirigidos a la glucosa.
MX2017014375A (es) Moduladores del ccr2.
TW201613919A (en) Inhibitors of Bruton&#39;s tyrosine kinase
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
UY36075A (es) Derivados de tubulisina
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
CU20160133A7 (es) Anticuerpos anti-mcam y métodos de uso asociados
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2018004050A (es) Inhibidores marcados con 18f mejorados del antigeno prostatico especifico de membrana (psma) y su uso como agentes de formacion de imagenes para el cancer de prostata.
MX386476B (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
CL2018000131A1 (es) Inmunoconjugados de il22
MA40535A (fr) Imagerie et thérapie d&#39;une inflammation et d&#39;une infection ciblant hsp90
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX382476B (es) Dispersiones solidas de bendamustina e infusion continua.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.